Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Bortezomib and vorinostat in refractory acute myelogenous leukemia and high-risk myelodysplastic syndromes: produces stable disease but at the cost of high toxicity.

× No keyword cloud information.

5 in total

1. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.

Authors: Liang Zhou; Shuang Chen; Yu Zhang; Maciej Kmieciak; Yun Leng; Lihong Li; Hui Lin; Kathryn A Rizzo; Catherine I Dumur; Andrea Ferreira-Gonzalez; Mohamed Rahmani; Lawrence Povirk; Sri Chalasani; Allison J Berger; Yun Dai; Steven Grant
Journal: Blood Date: 2016-02-05 Impact factor: 22.113

Review 2. Targeting the ubiquitin pathway for cancer treatment.

Authors: Jia Liu; Shavali Shaik; Xiangpeng Dai; Qiong Wu; Xiuxia Zhou; Zhiwei Wang; Wenyi Wei
Journal: Biochim Biophys Acta Date: 2014-12-04

3. Crotonoside exhibits selective post-inhibition effect in AML cells via inhibition of FLT3 and HDAC3/6.

Authors: Yu-Zhi Li; Si Yu; Pei-Ao Yan; Dao-Yin Gong; Fang-Li Wu; Zhi He; Yu-Yao Yuan; An-Yan Zhao; Xue Tang; Ruo-Qi Zhang; Cheng Peng; Zhi-Xing Cao
Journal: Oncotarget Date: 2017-09-08

Review 4. The role of the proteasome in AML.

Authors: C M Csizmar; D-H Kim; Z Sachs
Journal: Blood Cancer J Date: 2016-12-02 Impact factor: 11.037

5. Loss of FBXO9 Enhances Proteasome Activity and Promotes Aggressiveness in Acute Myeloid Leukemia.

Authors: R Willow Hynes-Smith; Samantha A Swenson; Heather Vahle; Karli J Wittorf; Mika Caplan; Catalina Amador; R Katherine Hyde; Shannon M Buckley
Journal: Cancers (Basel) Date: 2019-11-03 Impact factor: 6.639

5 in total